Switch to
More onapp

Eris Lifesciences Ltd

ERIS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹8,557 cr, stock is ranked 373
Low RiskStock is 1.41x as volatile as Nifty
612.4016.85 (-2.68%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹8,557 cr, stock is ranked 373
Low RiskStock is 1.41x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
21.07
PB RatioPB Ratio
4.48
Dividend YieldDiv. Yield
0.95%
Sector PESector PE
34.26
Sector PBSector PB
4.19
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market

Investor PresentationView older 

Jan 17, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120221.011.091.221.370.290.300.360.41
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJan 23, 2023

Eris Lifesciences Limited has informed the Exchange about Transcript | Download

Eris Lifesciences Limited has informed the Exchange about Transcript | Download

Updates 
Announced OnJan 23, 2023

Eris Lifesciences Limited has informed the Exchange regarding 'INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015'. | Download

Eris Lifesciences Limited has informed the Exchange regarding 'INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015'. | Download

Cash Dividend 
Ex. DateAug 11, 2022

Interim • Div/Share: ₹ 7.35

See all events